UBS Group
VRCA icon

UBS Group’s Verrica Pharmaceuticals VRCA Stock Holding History

UBS Group’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.6K Buy
4,270
+4,246
+17,692% +$27.2K ﹤0.01% 7847
2025
Q4 		$199 Sell
24
-41,608
-100% -$231K ﹤0.01% 10109
2025
Q3 		$179K Buy
41,632
+34,359
+472% +$207K ﹤0.01% 6733
2025
Q2 		$38.5K Sell
7,273
-71,743
-91% -$386K ﹤0.01% 7988
2025
Q1 		$349K Buy
79,016
+61,610
+354% +$398K ﹤0.01% 6126
2024
Q4 		$122K Buy
17,406
+16,445
+1,711% +$181K ﹤0.01% 6752
2024
Q3 		$13.9K Buy
961
+327
+52% +$14.7K ﹤0.01% 7559
2024
Q2 		$46.2K Sell
634
-1,599
-72% -$123K ﹤0.01% 6750
2024
Q1 		$132K Sell
2,233
-196
-8% -$10.8K ﹤0.01% 6095
2023
Q4 		$178K Buy
2,429
+1,316
+118% +$54.1K ﹤0.01% 5847
2023
Q3 		$43.2K Sell
1,113
-183
-14% -$9.3K ﹤0.01% 6383
2023
Q2 		$74.8K Buy
1,296
+1,121
+641% +$68.1K ﹤0.01% 6220
2023
Q1 		$11.4K Sell
175
-16
-8% -$968 ﹤0.01% 7506
2022
Q4 		$5.26K Sell
191
-360
-65% -$9.61K ﹤0.01% 9198
2022
Q3 		$16K Buy
551
+210
+62% +$7.2K ﹤0.01% 7714
2022
Q2 		$7K Buy
341
+60
+21% +$3.02K ﹤0.01% 8538
2022
Q1 		$23K Sell
281
-155
-36% -$12.8K ﹤0.01% 7306
2021
Q4 		$40K Buy
436
+51
+13% +$5.78K ﹤0.01% 7131
2021
Q3 		$48K Sell
385
-379
-50% -$42.5K ﹤0.01% 6373
2021
Q2 		$86K Sell
764
-228
-23% -$27.6K ﹤0.01% 5999
2021
Q1 		$150K Buy
992
+381
+62% +$52.7K ﹤0.01% 5659
2020
Q4 		$71K Buy
611
+298
+95% +$27.4K ﹤0.01% 5919
2020
Q3 		$24K Sell
313
-421
-57% -$34.5K ﹤0.01% 6169
2020
Q2 		$81K Sell
734
-364
-33% -$42.1K ﹤0.01% 5475
2020
Q1 		$120K Sell
1,098
-773
-41% -$102K ﹤0.01% 5131
2019
Q4 		$298K Buy
1,871
+476
+34% +$70.2K ﹤0.01% 5299
2019
Q3 		$206K Buy
1,395
+960
+221% +$107K ﹤0.01% 5227
2019
Q2 		$50K Buy
435
+220
+102% +$20.6K ﹤0.01% 5935
2019
Q1 		$24K Sell
215
-201
-48% -$23.2K ﹤0.01% 6152
2018
Q4 		$34K Buy
416
+78
+23% +$9.47K ﹤0.01% 6392
2018
Q3 		$55K Buy
338
+327
+2,973% +$55.9K ﹤0.01% 6094
2018
Q2 		$2K Buy
+11
New +$2.15K ﹤0.01% 7743

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's VRCA Position: Q1 2026 in Review

UBS Group increased its Verrica Pharmaceuticals (VRCA) stake by 17,692% in Q1 2026, buying an estimated $27.2K and bringing the position to 4,270 shares worth $22.6K. The position accounts for ﹤0.01% of the portfolio, ranked #7847.

UBS Group first reported a position in VRCA in Q2 2018 and has held it in 32 quarters since. The position peaked at $349K in Q1 2025. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • UBS Group held 4,270 shares of Verrica Pharmaceuticals worth $22.6K as of Q1 2026.
  • UBS Group bought 4,246 Verrica Pharmaceuticals shares in Q1 2026, an estimated $27.2K.
  • Verrica Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7847 holding.
  • UBS Group first reported a position in Verrica Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
  • UBS Group's Verrica Pharmaceuticals position peaked at $349K in Q1 2025.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.